{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:04:25Z","timestamp":1790946265060,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Defense Health Board (Member), Entegrion (Board of Directors), Vitalant (Board of Directors), Securisyn (Royalties), Novartis Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Factors predicting allogeneic hematopoietic cell transplantation (HCT) outcomes in myelofibrosis in the early post-HCT period have not been defined thus far. We attempt to study such factors that can help identify patients at a higher risk of relapse or death. This retrospective study included 79 patients who underwent first HCT for myelofibrosis at three centers between 2005 and 2016. Univariate analysis showed that red blood cell (RBC) transfusion dependence (HR 9.02, 95% CI 4.0\u201320.35), platelet transfusion dependence (HR 8.17, 95%CI 3.83\u201317.37), 100% donor chimerism in CD33\u2009+\u2009cells (HR 0.21, 95%CI 0.07\u20130.62), unfavorable molecular status (HR 4.41, 95%CI 1.87\u201310.39), normal spleen size (HR 0.42, 95%CI 0.19\u20130.94), grade \u2265 2 bone marrow fibrosis (vs. grade \u2264 1; HR 2.7, 95%CI 1.1\u20136.93) and poor graft function (HR 2.6, 95%CI 1.22\u20135.53) at day +100 were statistically significantly associated with relapse-free survival (RFS). RBC transfusion dependence and unfavorable molecular status were also statistically significant in the multivariate analysis. Patients in whom both of these factors were present had a significantly worse RFS when compared to those with one or none. While limited by a small sample size, we demonstrate the significance of transfusion dependence and molecular status at day +100 in predicting outcomes.<\/jats:p>","DOI":"10.1038\/s41408-020-0302-9","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T13:03:25Z","timestamp":1583845405000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6850-6823","authenticated-orcid":false,"given":"Katie L.","family":"Kunze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Mountjoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K.","family":"Partain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Kosiorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4105","authenticated-orcid":false,"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Slack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena D. S.","family":"Fauble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose F.","family":"Leis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Sproat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,10]]},"reference":[{"key":"302_CR1","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.3324\/haematol.2018.205211","volume":"104","author":"M Robin","year":"2019","unstructured":"Robin, M. et al. Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica 104, 1782\u20131788 (2019).","journal-title":"Haematologica"},{"key":"302_CR2","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","volume":"114","author":"N Kroger","year":"2009","unstructured":"Kroger, N. et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114, 5264\u20135270 (2009).","journal-title":"Blood"},{"key":"302_CR3","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror, M. L. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106, 2912\u20132919 (2005).","journal-title":"Blood"},{"key":"302_CR4","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/blood-2011-08-372904","volume":"119","author":"BL Scott","year":"2012","unstructured":"Scott, B. L. et al. The dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 119, 2657\u20132664 (2012).","journal-title":"Blood"},{"key":"302_CR5","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3324\/haematol.2011.061168","volume":"97","author":"M Ditschkowski","year":"2012","unstructured":"Ditschkowski, M. et al. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis. Haematologica 97, 1574\u20131581 (2012).","journal-title":"Haematologica"},{"key":"302_CR6","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.bbmt.2019.01.002","volume":"25","author":"R Tamari","year":"2019","unstructured":"Tamari, R. et al. Impact of high-molecular-risk mutations on transplantation outcomes in patients with myelofibrosis. Biol. Blood Marrow Transplant. 25, 1142\u20131151 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"302_CR7","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","volume":"23","author":"N Kroger","year":"2017","unstructured":"Kroger, N. et al. Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 23, 1095\u20131101 (2017).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"302_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","volume":"20","author":"V Gupta","year":"2014","unstructured":"Gupta, V. et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol. Blood Marrow Transplant. 20, 89\u201397 (2014).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"302_CR9","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2014-04-572545","volume":"124","author":"D Rondelli","year":"2014","unstructured":"Rondelli, D. et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood 124, 1183\u20131191 (2014).","journal-title":"Blood"},{"key":"302_CR10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41409-018-0226-1","volume":"54","author":"T Jain","year":"2019","unstructured":"Jain, T. et al. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplant 54, 204\u2013211 (2019).","journal-title":"Bone Marrow Transplant"},{"key":"302_CR11","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.bbmt.2016.02.019","volume":"22","author":"M Robin","year":"2016","unstructured":"Robin, M. et al. Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis. Biol. Blood Marrow Transplant. 22, 1206\u20131211 (2016).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"302_CR12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat, N. et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J. Clin. Oncol. 29, 392\u2013397 (2011). 2011.","journal-title":"J. Clin. Oncol."},{"key":"302_CR13","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl, T. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med. 369, 2379\u20132390 (2013).","journal-title":"N. Engl. J. Med."},{"key":"302_CR14","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia, J. et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med. 369, 2391\u20132405 (2013).","journal-title":"N. Engl. J. Med."},{"key":"302_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman, Y. et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3, e270 (2006).","journal-title":"PLoS Med."},{"key":"302_CR16","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.bbmt.2013.03.018","volume":"19","author":"GS Booth","year":"2013","unstructured":"Booth, G. S., Gehrie, E. A., Bolan, C. D. & Savani, B. N. Clinical guide to ABO-incompatible allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 19, 1152\u20131158 (2013).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"302_CR17","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/aje\/kwk052","volume":"165","author":"E Vittinghoff","year":"2007","unstructured":"Vittinghoff, E. & McCulloch, C. E. Relaxing the rule of ten events per variable in logistic and Cox regression. Am. J. Epidemiol. 165, 710\u2013718 (2007).","journal-title":"Am. J. Epidemiol."},{"key":"302_CR18","unstructured":"Srour, S. A. et al. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica (2019). [Epub ahead of print]."},{"key":"302_CR19","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1182\/blood-2009-12-260588","volume":"116","author":"H Alchalby","year":"2010","unstructured":"Alchalby, H. et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 116, 3572\u20133581 (2010).","journal-title":"Blood"},{"key":"302_CR20","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/bmt.2009.367","volume":"45","author":"H Alchalby","year":"2010","unstructured":"Alchalby, H. et al. Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. Bone Marrow Transplant. 45, 1404\u20131407 (2010).","journal-title":"Bone Marrow Transplant."},{"key":"302_CR21","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1182\/blood-2008-11-190975","volume":"113","author":"N Kroger","year":"2009","unstructured":"Kroger, N. et al. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 113, 1866\u20131868 (2009).","journal-title":"Blood"},{"key":"302_CR22","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.bbmt.2014.02.019","volume":"20","author":"N Kroger","year":"2014","unstructured":"Kroger, N. et al. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis. Biol. Blood Marrow Transplant. 20, 812\u2013815 (2014).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"302_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1182\/blood.V126.23.56.56","volume":"126","author":"S Verstovsek","year":"2015","unstructured":"Verstovsek, S. et al. PRM-151 in myelofibrosis: durable efficacy and safety at 72 weeks. Blood 126, 56\u201356 (2015).","journal-title":"Blood"},{"key":"302_CR24","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.exphem.2006.07.004","volume":"34","author":"JC Wang","year":"2006","unstructured":"Wang, J. C. et al. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia. Exp. Hematol. 34, 1617\u20131623 (2006).","journal-title":"Exp. Hematol."},{"key":"302_CR25","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1182\/blood-2004-04-1320","volume":"105","author":"AM Vannucchi","year":"2005","unstructured":"Vannucchi, A. M. et al. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood 105, 3493\u20133501 (2005).","journal-title":"Blood"},{"key":"302_CR26","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/10428190290016809","volume":"43","author":"A Schmitt","year":"2002","unstructured":"Schmitt, A. et al. Polymorphonuclear neutrophil and megakaryocyte mutual involvement in myelofibrosis pathogenesis. Leuk. Lymphoma 43, 719\u2013724 (2002).","journal-title":"Leuk. Lymphoma"},{"key":"302_CR27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3109\/10428194.2013.805329","volume":"55","author":"J Mascarenhas","year":"2014","unstructured":"Mascarenhas, J. et al. Anti-transforming growth factor-beta therapy in patients with myelofibrosis. Leuk. Lymphoma 55, 450\u2013452 (2014).","journal-title":"Leuk. Lymphoma"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0302-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0302-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0302-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:26:31Z","timestamp":1670250391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0302-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,10]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["302"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-0302-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,10]]},"assertion":[{"value":"6 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.N.: Defense Health Board (Member), Entegrion (Board of Directors), Vitalant (Board of Directors), Securisyn (Royalties), Novartis Pharmaceuticals (spouse is an employee). R.A.M.: (Consultant) Novartis, Sierra Onc, LaJolla, Pharma; (Research Support) Celgene, Incyte, Abbvie, Samus, Genotech, Promedior, CTI.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"36"}}